Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy

Anna Elisabetta Brunetti1, Sabina Delcuratolo2, Vito Lorusso3

  • 1Medical Oncology Unit, National Cancer Institute "Giovanni Paolo II", Bari, Italy brunetti.ae@gmail.com.

Anticancer Research
|July 2, 2014
PubMed
Abstract

Insights

Trabectedin, a marine-derived drug, showed prolonged partial response in a heavily pre-treated patient with desmoplastic small round cell tumour (DSRCT). This suggests trabectedin as a potential option for managing this rare cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Desmoplastic small round cell tumour (DSRCT) is an aggressive cancer primarily affecting young males, with limited treatment options and poor prognosis.
  • Current DSRCT management involves intensive multi-agent chemotherapy, surgery, radiation, and potentially autologous stem cell transplantation or HIPEC.

Observation:

  • A single patient with heavily pre-treated DSRCT, refractory to conventional therapies, received third-line treatment with trabectedin.
  • Trabectedin is a marine-derived antineoplastic agent with multi-target activity.

Findings:

  • The patient experienced a prolonged partial response and an extended period of stable disease after trabectedin administration.
  • This response was observed following disease progression despite prior multi-agent chemotherapy, HIPEC, and surgery.

Implications:

  • Trabectedin demonstrates potential as a valuable component in the multimodal treatment strategy for DSRCT.
  • Further research is warranted to investigate the efficacy and impact of trabectedin in DSRCT management.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.1K